PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsPeginterferon alfa-2a
Peginterferon alfa-2a
Pegasys (peginterferon alfa-2a) is a protein pharmaceutical. Peginterferon alfa-2a was first approved as Pegasys on 2002-06-20. It is used to treat brain neoplasms, chronic hepatitis b, chronic hepatitis c, colorectal neoplasms, and cryoglobulinemia amongst others in the USA. It has been approved in Europe to treat chronic hepatitis b and chronic hepatitis c.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
neoplasmsD009369
digestive system diseasesD004066
nervous system diseasesD009422
eye diseasesD005128
urogenital diseasesD000091642
cardiovascular diseasesD002318
hemic and lymphatic diseasesD006425
skin and connective tissue diseasesD017437
immune system diseasesD007154
Show 1 more
Trade Name
FDA
EMA
Pegasys (discontinued: Pegasys)
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Peginterferon alfa-2a
+
Ribavirin
Tradename
Proper name
Company
Number
Date
Products
Pegasys Copegus Combination Packpeginterferon alfa-2a and ribavirinRocheN-125083 DISCN2004-06-04
3 products
Hide discontinued
Peginterferon alfa-2a
Tradename
Proper name
Company
Number
Date
Products
Pegasyspeginterferon alfa-2aPharma&N-103964 RX2002-10-16
2 products
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
pegasysBiologic Licensing Application2026-10-16
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L03: Immunostimulants
— L03A: Immunostimulants
— L03AB: Interferons
— L03AB11: Peginterferon alfa-2a
— L03AB61: Peginterferon alfa-2a, combinations
HCPCS
No data
Clinical
Clinical Trials
716 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HepatitisD006505—K75.92213710812881455
Hepatitis aD006506EFO_0007305B15191159512675412
Hepatitis cD006526—B19.2201281079955388
Chronic hepatitis cD019698EFO_0004220B18.21492817848300
Chronic hepatitisD006521—K73.91246374825157
Chronic hepatitis bD019694EFO_0004239B18.11439234829145
Hepatitis bD006509——1030234535138
Hiv infectionsD015658EFO_0000764B205201210245
InfectionsD007239EFO_0000544—21766231
Liver cirrhosisD008103EFO_0001422K74.0—352917
Show 32 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Renal cell carcinomaD002292EFO_0000376—2146—120
Hepatitis dD003699EFO_0007304—183—314
LeukemiaD007938—C95284—113
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_0000340——77——12
Essential thrombocythemiaD013920—D47.3144——9
MelanomaD008545——264——9
Chronic hepatitis dD019701——143—18
Polycythemia veraD011087—D45133——7
ThrombocytosisD013922—D75.83132——6
Myeloid leukemiaD007951—C92151——6
Show 16 more
Indications Phases 2
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———8———19
Kaposi sarcomaD012514—C462————2
PsoriasisD011565EFO_0000676L401————1
Hepatic insufficiencyD048550——1————1
Plexiform neurofibromaD018318EFO_0000658—1————1
NeurofibromaD009455EFO_0000622—1————1
HemangiosarcomaD006394——1————1
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePeginterferon alfa-2a
INNpeginterferon alfa-2a
Description
Interferon alpha-2 precursor (Interferon alpha-A) (LeIF A)
Classification
Protein
Drug classPEGylated compounds, covalent attachment of macrogol (polyethylene glycol) polymer
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL1201560
ChEBI ID—
PubChem CID—
DrugBankDB00008
UNII IDQ46947FE7K (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 8,448 documents
View more details
Safety
Black-box Warning
Black-box warning for: Pegasys
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
63,458 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use